Fig. 3From: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritisKaplan–Meier plot: Time to first GCA flare after clinical remission until 52W (ITT population). Note: Time (days) is calculated from randomization to first GCA flare after clinical remission up to week 52. GCA, giant cell arteritis; ITT, intent-to-treat; PBO, placebo; SAR150/200, sarilumab 150/200 mg; W, weekBack to article page